NCT01140685

Brief Summary

This work will focus on the anti-inflammatory and antioxidant pathways in lung diseases by measuring HO-1 in induced sputum and CO in exhaled air in cases of four respiratory diseases, asthma, chronic obstructive pulmonary disease (COPD), occupational lung diseases (OLD) and interstitial lung disease (ILD).

Trial Health

50
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2009

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

February 17, 2010

Completed
4 months until next milestone

First Posted

Study publicly available on registry

June 9, 2010

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2010

Completed
Last Updated

June 9, 2010

Status Verified

March 1, 2010

Enrollment Period

9 months

First QC Date

February 17, 2010

Last Update Submit

June 8, 2010

Conditions

Lung Diseases

Keywords

mucus-stimulated (induced sputum)lung disease (asthma, COPD, ILD and OLD)HO-1 (heme oxigenase-1)oxidative stressCO (carbon monoxide)The oxidative stress in lung diseases

Outcome Measures

Primary Outcomes (1)

  • exhaled CO levels

    2010-2011

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Fifty adult male and female patients who had been diagnosed with one or more of the four study diseases and referred for sputum induction to the Pulmonary Laboratory in the Tel-Aviv Sourasky Medical Center will be enrolled

You may qualify if:

  • Male and female
  • Ages \>/= 18 years
  • Diagnosed with one or more lung diseases
  • Referred for sputum induction to the Pulmonary Laboratory in the Tel-Aviv Sourasky Medical Center

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITHOUT DNA

induced sputum, exhaled CO levels

MeSH Terms

Conditions

Lung DiseasesAsthmaPulmonary Disease, Chronic ObstructiveLung Diseases, Interstitial

Condition Hierarchy (Ancestors)

Respiratory Tract DiseasesBronchial DiseasesLung Diseases, ObstructiveRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Elizabeth Fierman, PHD

    Tel Aviv Sorasky Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

February 17, 2010

First Posted

June 9, 2010

Study Start

December 1, 2009

Primary Completion

September 1, 2010

Last Updated

June 9, 2010

Record last verified: 2010-03